ANDOVER, Mass. - TransMedics Group, Inc. (NASDAQ:TMDX), a medical technology company specializing in organ transplant therapy, has scheduled the release of its financial results for the fourth quarter and full year of 2023 for after the market closes on February 26, 2024. The announcement was made today, with further details indicating that the company's management will hold a conference call on the same day at 4:30 p.m. ET to discuss the earnings report.
The call will be accessible to both domestic and international investors. Participants can join the call by dialing (866) 807-9684 within the United States or (412) 317-5415 for calls originating outside the country and requesting to be connected to the TransMedics call. Additionally, a live webcast, as well as an archived version, will be made available on the TransMedics website under the "Investors" section.
TransMedics, headquartered in Andover, Massachusetts, claims to be the global leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. The company's innovative technologies focus on maintaining organ quality, evaluating organ viability before transplantation, and potentially increasing the number of donor organs available for patients with end-stage heart, lung, and liver diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.